Myricetin as a therapeutic agent: Molecular researches and clinical potentia

Myricetin is a polyphenolic flavonol that is commonly present in tea, grapes, fruits, vegetables, and a number of medicinal plants. It is known to have a number of biological actions that are important for human health. Myricetin stands out for its multifunctional potential in the prevention and treatment of different infectious and degenerative disorders, especially as interest in natural bioactive chemicals grows. The primary mechanism entails robust antioxidant action by scavenging reactive oxygen species (ROS) and inducing the endogenous enzymes like catalase and superoxide dismutase. Furthermore, myricetin has anti-inflammatory properties via inhibiting the activation of the MAPK (mitogen-activated protein kinase) and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathways, which lowers the synthesis of proinflammatory cytokines. Numerous in vitro and in vivo investigations have demonstrated its capacity to suppress the growth of cancer cells, trigger apoptosis, and stop metastasis in the context of oncology. Myricetin decreases cholesterol, promotes endothelial function, and guards against atherosclerosis in the cardiovascular system. Its neuroprotective benefits are also encouraging, especially in terms of protecting dopamine in Parkinson’s disease and preventing β-amyloid buildup in Alzheimer’s disease. Furthermore, myricetin is important for preventing diabetes and obesity because it regulates blood glucose, improves insulin sensitivity, and modifies lipid metabolism. Antimicrobial and antiviral activities have also been documented, although they are still limited to experimental studies. Nevertheless, two significant obstacles to its conversion to practical applications are the lack of extensive clinical trials and the limited oral bioavailability. Future studies will concentrate on developing novel formulations, investigating safe and efficient dosages, and conducting thorough clinical trials. All things considered, myricetin shows significant promise as a  multipurpose natural therapeutic candidate that promotes human health.

1. Dias, M. C., Pinto, D. C. G. A., Silva, A. M. S. (2021). Plant flavonoids: Chemical characteristics and biological activity. Molecules, 26(17), Article 5377. https://doi.org/10.3390/molecules26175377

2. Panche, A. N., Diwan, A. D., Chandra, S. R. (2016). Flavonoids: An overview. Journal of Nutritional Science, 5(1), Article e47. https://doi.org/10.1017/jns.2016.41

3. Zahra, M., Abrahamse, H., George, B. P. (2024). Flavonoids: Antioxidant powerhouses and their role in nanomedicine. Antioxidants, 13(8), Article 922. https://doi.org/10.3390/antiox13080922

4. Agraharam, G., Girigoswami, A., Girigoswami, K. (2022). Myricetin: A multifunctional flavonol in biomedicine. Current Pharmacology Reports, 8(1), 48–61. https://doi.org/10.1007/s40495-021-00269-2

5. Taheri, Y., Suleria, H. A. R., Martins, N., Sytar, O., Beyatli, A., Yeskaliyeva, B. et al. (2020). Myricetin bioactive effects: Moving from preclinical evidence to potential clinical applications. BMC Complementary Medicine and Therapies, 20(1), Article 241. https://doi.org/10.1186/s12906-020-03033‑z

6. Almatroodi, S. A., Rahmani, A. H. (2025). Unlocking the pharmacological potential of myricetin against various pathogenesis. International Journal of Molecular Sciences, 26(9), Article 4188. https://doi.org/10.3390/ijms26094188

7. Jiang, M., Zhu, M., Wang, L., Yu, S. (2019). Anti-tumor effects and associated molecular mechanisms of myricetin. Biomedicine and Pharmacotherapy, 120, Article 109506. https://doi.org/10.1016/j.biopha.2019.109506

8. Sethiya, N. K., Ghiloria, N., Srivastav, A., Bisht, D., Chaudhary, S. K., Walia, V. et al. (2024). Therapeutic potential of myricetin in the treatment of neurological, neuropsychiatric, and neurodegenerative disorders. CNS and Neurological Disorders — Drug Targets, 23(7), 865–882. https://doi.org/10.2174/1871527322666230718105358

9. Coêlho, C. F. F., Souza, I. L. S., Chagas, V. T., Ribeiro, N. L. X., Pinto, B. A. S., França, L. M. et al. (2021). Myricetin improves metabolic outcomes but not cognitive deficit associated to metabolic syndrome in male mice. Food and Function, 12(8), 3586–3596. https://doi.org/10.1039/d1fo00073j

10. Li, J., Luo, T., Zhao, Y., Wang, D., Jin, Y., Wu, Z. et al. (2024). Cardioprotective potentials of myricetin on doxorubicin-induced cardiotoxicity based on biochemical and transcriptomic analysis. Biomedicine and Pharmacotherapy, 175(1), Article 116748. https://doi.org/10.1016/j.biopha.2024.116748

11. Imran, M., Saeed, F., Hussain, G., Imran, A., Mehmood, Z., Gondal, T. A. et al. (2021). Myricetin: A comprehensive review on its biological potentials. Food Science and Nutrition, 9(10), 5854–5868. https://doi.org/10.1002/fsn3.2513

12. Park, K. -S., Chong, Y., Kim, M. K. (2016). Myricetin: Biological activity related to human health. Applied Biological Chemistry, 59(1), 259–269. https://doi.org/10.1007/s13765-016-0150-2

13. Semwal, D. K., Semwal, R. B., Combrinck, S., Viljoen, A. (2016). Myricetin: A dietary molecule with diverse biological activities. Nutrients, 8(2), Article 90. https://doi.org/10.3390/nu8020090

14. Javed, Z., Khan, K., Herrera-Bravo, J., Naeem, S., Iqbal, M. J., Raza, Q. et al. (2022). Myricetin: Targeting signaling networks in cancer and its implication in chemotherapy. Cancer Cell International, 22(1), Article 239. https://doi.org/10.1186/s12935-022-02663-2

15. Wang, L., Tang, Z., Li, B., Peng, Y., Yang, X., Xiao, Y. et al. (2024). Myricetin ameliorates cognitive impairment in 3×Tg Alzheimer’s disease mice by regulating oxidative stress and tau hyperphosphorylation. Biomedicine and Pharmacotherapy, 177, Article 116963. https://doi.org/10.1016/j.biopha.2024.116963

16. Li, Y., Zheng, X., Yi, X., Liu, C., Kong, D., Zhang, J. et al. (2017). Myricetin: A potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist. FASEB Journal, 31(6), 2603–2611. https://doi.org/10.1096/fj.201601339R

17. Meng, Z., Wang, M., Xing, J., Liu, Y., Li, H. (2019). Myricetin ameliorates atherosclerosis in the low-density-lipoprotein receptor knockout mice by suppression of cholesterol accumulation in macrophage foam cells. Nutrition and Metabolism, 16(1), Article 25. https://doi.org/10.1186/s12986-019-0354-7

18. Goyal, A., Sikarwar, O., Verma, A., Solanki, K., Agrawal, N., Dubey, N. et al. (2024). Unveiling myricetin’s pharmacological potency: A comprehensive exploration of the molecular pathways with special focus on PI3K/AKT and Nrf2 signaling. Journal of Biochemical and Molecular Toxicology, 38(6), Article e23739. https://doi.org/10.1002/jbt.23739

19. Rahmani, A. H., Almatroudi, A., Allemailem, K. S., Alwanian, W. M., Alharbi, B. F., Alrumaihi, F. et al. (2023). Myricetin: A significant emphasis on its anticancer potential via the modulation of inflammation and signal transduction pathways. International Journal of Molecular Sciences, 24(11), Article 9665. https://doi.org/10.3390/ijms24119665

20. Afroze, N., Pramodh, S., Hussain, A., Waleed, M., Vakharia, K. (2020). A review on myricetin as a potential therapeutic candidate for cancer prevention. 3 Biotech, 10(5), Article 211. https://doi.org/10.1007/s13205-020-02207-3

21. Ozcan, C., Yaman, M. (2014). Determination of myricetin in medicinal plants by high-performance liquid chromatography. Instrumentation Science and Technology, 43(1), 44–52. https://doi.org/10.1080/10739149.2014.940533

22. Barzegar, A. (2016). Antioxidant activity of polyphenolic myricetin in vitro cell-free and cell-based systems. Molecular Biology Research Communications, 5(2), 87–95.

23. Bouyahya, A., El Omari, N., El Hachlafi, N., El Jemly, M., Hakkour, M., Balahbib, A. et al. (2022). Chemical compounds of berry-derived polyphenols and their effects on gut microbiota, inflammation, and cancer. Molecules, 27(10), Article 3286. https://doi.org/10.3390/molecules27103286

24. Janabi, A. H. W., Kamboh, A. A., Saeed, M., Xiaoyu, L., Bibi, J., Majeed, F. et al. (2020). Flavonoid-rich foods (FRF): A promising nutraceutical approach against lifespan-shortening diseases. Iranian Journal of Basic Medical Sciences, 23(2), 140–153. https://doi.org/10.22038/IJBMS.2019.35125.8353

25. Sabra, A., Netticadan, T., Wijekoon, C. (2021). Grape bioactive molecules, and the potential health benefits in reducing the risk of heart diseases. Food Chemistry: X, 12(1), Article 100149. https://doi.org/10.1016/j.fochx.2021.100149

26. Lombardo, M., Feraco, A., Camajani, E., Caprio, M., Armani, A. (2023). Health effects of red wine consumption: A narrative review of an issue that still deserves debate. Nutrients, 15(8), Article 1921. https://doi.org/10.3390/nu15081921

27. Suriyaprom, S., Mosoni, P., Leroy, S., Kaewkod, T., Desvaux, M., Tragoolpua, Y. (2022). Antioxidants of fruit extracts as antimicrobial agents against pathogenic bacteria. Antioxidants, 11(3), Article 602. https://doi.org/10.3390/antiox11030602

28. Chen, S., Wang, X., Cheng, Y., Gao, H., Chen, X. (2023). A review of classification, biosynthesis, biological activities and potential applications of flavonoids. Molecules, 28(13), Article 4982. https://doi.org/10.3390/molecules28134982

29. Chagas, M. do S. S., Behrens, M. D., Moragas-Tellis, C. J., Penedo, G. X. M., Silva, A. R., Gonçalves-de-Albuquerque, C. F. (2022). Flavonols and flavones as potential antiinflammatory, antioxidant, and antibacterial compounds. Oxidative Medicine and Cellular Longevity, 2022(1), Article 9966750. https://doi.org/10.1155/2022/9966750

30. Mahmud, A. R., Ema, T. I., Siddiquee, M. F.-R., Shahriar, A., Ahmed, H., MosfeqUl-Hasan, M. et al. (2023). Natural flavonols: Actions, mechanisms, and potential therapeutic utility for various diseases. Beni-­Suef University Journal of Basic and Applied Sciences, 12(1), Article 47. https://doi.org/10.1186/s43088-023-00387-4

31. Raiola, A., Errico, A., Petruk, G., Monti, D. M., Barone, A., Rigano, M. M. (2017). Bioactive compounds in Brassicaceae vegetables with a role in the prevention of chronic diseases. Molecules, 23(1), Article 15. https://doi.org/10.3390/molecules23010015

32. Aboulwafa, M. M., Youssef, F. S., Gad, H. A., Altyar, A. E., Al-Azizi, M. M., Ashour, M. L. (2019). A comprehensive insight on the health benefits and phytoconstituents of Camellia sinensis and recent approaches for its quality control. Antioxidants, 8(10), Article 455. https://doi.org/10.3390/antiox8100455

33. Aydemir, M. E., Takım, K., Yılmaz, M. A. (2023). Characterization of phenolic components of black teas of different origins and the effect of brewing duration on quality properties. Food Science and Nutrition, 12(1), 494–507. https://doi.org/10.1002/fsn3.3782

34. Zhao, Z., Chen, R., Ng, K. (2024). Effects of differently processed tea on the gut microbiota. Molecules, 29(17), Article 4020. https://doi.org/10.3390/molecules29174020

35. Alemu, T. T., Abdullahi, M. A., Abamecha, N., Hamza, M. (2025). Contribution of nutritional and bioactive components of tea leaves in management of noncommunicable chronic diseases: A comprehensive review. Discover Food, 5(1), Article 252. https://doi.org/10.1007/s44187-025-00456‑w

36. Georgiev, V., Ananga, A., Tsolova, V. (2014). Recent advances and uses of grape flavonoids as nutraceuticals. Nutrients, 6(1), 391–415. https://doi.org/10.3390/nu6010391

37. González-Paramás, A. M., Esteban-Ruano, S., Santos-Buelga, C., de Pascual-Teresa, S., Rivas-Gonzalo, J. C. (2004). Flavanol content and antioxidant activity in winery byproducts. Journal of Agricultural and Food Chemistry, 52(2), 234–238. https://doi.org/10.1021/jf0348727

38. Castaldo, L., Narváez, A., Izzo, L., Graziani, G., Gaspari, A., Minno, G. D. et al. (2019). Red wine consumption and cardiovascular health. Molecules, 24(19), Article 3626. https://doi.org/10.3390/molecules24193626

39. Zhang, X., Huang, H., Zhang, Q., Fan, F., Xu, C., Sun, C. et al. (2015). Phytochemical characterization of Chinese bayberry (Myrica rubra Sieb. et Zucc.) of 17 cultivars and their antioxidant properties. International Journal of Molecular Sciences, 16(6), 12467–12481. https://doi.org/10.3390/ijms160612467

40. Arumugam, B., Manaharan, T., Heng, C.K., Kuppusamy, U. R., Palanisamy, U. D. (2014). Antioxidant and antiglycemic potentials of a standardized extract of Syzygium malaccense. LWT — Food Science and Technology, 59(2, Part 1), 707–712. https://doi.org/10.1016/j.lwt.2014.06.041

41. Nurlely, N., Putra, A. M. P., Nurrochmad, A., Widyarini, S., Fakhrudin, N. (2024). Extraction, phytochemicals, bioactivities, and toxicity of Syzygium polyanthum: A comprehensive review. Journal of Herbmed Pharmacology, 13(3), 366–380. https://doi.org/10.34172/jhp.2024.51454

42. Pratama, B. P., Pranoto, Y., Supriyadi, Swasono, R. T. (2023). The properties of salam leaf extract (Syzygium polyanthum) with different solvent ratio and processing time using ultrasonication-assisted extraction method. Chemical Engineering Journal, 26(4), 581–587. https://doi.org/10.6180/jase.202304_26(4).0015

43. Misgiati, M., Winarni, I., Murniasih, T., Novriyanti, E., Tarman, K., Safithri, M. et al. (2024). The anticancer and antioxidant potential of local sea cucumber Holothuria edulis, an ecology balancer of Labuan Bajo marine ecosystem. Case Studies in Chemical and Environmental Engineering, 9(3), Article 100625. https://doi.org/10.1016/j.cscee.2024.100625

44. Pratama, B. P., Pranoto, Y., Supriyadi, Swasono, R. T. (2022). The identification of β-ocimene biosynthetic pathway through mevalonate acid (MVA) and 1‑deoxyD-xylulose 5‑phosphate (DXP) pathways using crude enzyme extracts in Indonesian bay leaf/salam leaf (Syzygium polyanthum). Tropical Life Sciences Research, 33(2), 1–18. https://doi.org/10.21315/tlsr2022.33.2.1

45. Zoratti, L., Karppinen, K., Escobar, A. L., Häggman, H., Jaakola, L. (2014). Lightcontrolled flavonoid biosynthesis in fruits. Frontiers in Plant Science, 5(1), Article 534. https://doi.org/10.3389/fpls.2014.00534

46. Manach, C., Scalbert, A., Morand, C., Rémésy, C., Jiménez, L. (2004). Polyphenols: Food sources and bioavailability. The American Journal of Clinical Nutrition, 79(5), 727–747. https://doi.org/10.1093/ajcn/79.5.727

47. Devi, K. P., Rajavel, T., Habtemariam, S., Nabavi, S. F., Nabavi, S. M. (2015). Molecular mechanisms underlying anticancer effects of myricetin. Life Sciences, 142, 19–25. https://doi.org/10.1016/j.lfs.2015.10.004

48. Parmenter, B. H., Thompson, A. S., Bondonno, N. P., Jennings, A., Murray, K., Perez-Cornago, A. et al. (2025). High diversity of dietary flavonoid intake is associated with a lower risk of all-cause mortality and major chronic diseases. Nature Food, 6(7), 668–680. https://doi.org/10.1038/s43016-025-01176-1

49. Su, H. M., Feng, L. N., Zheng, X. D., Chen, W. (2016). Myricetin protects against dietinduced obesity and ameliorates oxidative stress in C57BL/6 mice. Journal of Zhejiang University — SCIENCE B, 17(6), 437–446. https://doi.org/10.1631/jzus.B1600074

50. Deriabina, A., Prutskij, T., Ochoa, H. D. M., Jimenez, E. G., Deriabin, S. (2024). Comparative analysis of fluorescence emission in myricetin, kaempferol, and quercetin powders and solutions. International Journal of Molecular Sciences, 25(5), Article 2558. https://doi.org/10.3390/ijms25052558

51. Yao, Y., Lin, G., Xie, Y., Ma, P., Li, G., Meng, Q. et al. (2014). Preformulation studies of myricetin: A natural antioxidant flavonoid. Pharmazie, 69(1), 19–26.

52. Jomová, K., Hudecova, L., Lauro, P., Simunkova, M., Alwasel, S. H., Alhazza, I. M. et al. (2019). A switch between antioxidant and prooxidant properties of the phenolic compounds myricetin, morin, 3′,4′-dihydroxyflavone, taxifolin and 4‑hydroxy-coumarin in the presence of copper(II) ions: A spectroscopic, absorption titration and DNA damage study. Molecules, 24(23), Article 4335. https://doi.org/10.3390/molecules24234335

53. Satari, A., Ghasemi, S., Habtemariam, S., Asgharian, S., Lorigooini, Z. (2021). Rutin: A flavonoid as an effective sensitizer for anticancer therapy; Insights into multifaceted mechanisms and applicability for combination therapy. Evidence-Based Complementary and Alternative Medicine, 2021(1), Article 9913179. https://doi.org/10.1155/2021/9913179

54. Charlton, N. C., Mastyugin, M., Török, B., Török, M. (2023). Structural features of small molecule antioxidants and strategic modifications to improve potential bioactivity. Molecules, 28(3), Article 1057. https://doi.org/10.3390/molecules28031057

55. Sadasivam, K., Kumaresan, R. (2011). Antioxidant behavior of mearnsetin and myricetin flavonoid compounds — A DFT study. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 79(1), 282–293. https://doi.org/10.1016/j.saa.2011.02.042

56. Wu, C., He, L., Zhang, Y., You, C., Li, X., Jiang, P. et al. (2023). Separation of flavonoids with significant biological activity from Acacia mearnsii leaves. RSC Advances, 13(13), 9119–9127. https://doi.org/10.1039/d3ra00209h

57. Franklin, S. J., Myrdal, P. B. (2015). Solid-state and solution characterization of myricetin. AAPS PharmSciTech, 16(6), 1400–1408. https://doi.org/10.1208/s12249-015-0329-6

58. Yokomizo, A., Moriwaki, M. (2005). Myricitrin degraded by simulated digestion inhibits oxidation of human low-density lipoprotein. Bioscience, Biotechnology, and Biochemistry, 69(4), 693–699. https://doi.org/10.1271/bbb.69.693

59. Song, X., Tan, L., Wang, M., Ren, C., Guo, C., Yang, B. et al. (2021). Myricetin: A review of the most recent research. Biomedicine and Pharmacotherapy, 134, Article 111017. https://doi.org/10.1016/j.biopha.2020.111017

60. Wittig, J., Herderich, M., Graefe, E. U., Veit, M. (2001). Identification of quercetin glucuronides in human plasma by high-performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications, 753(2), 237–243. https://doi.org/10.1016/s0378-4347(00)00549-1

61. Huang, J., He, Z., Cheng, R., Cheng, Z., Wang, S., Wu, X. et al. (2020). Assessment of binding interaction dihydromyricetin and myricetin with bovine lactoferrin and effects on antioxidant activity. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 243(1), Article 118731. https://doi.org/10.1016/j.saa.2020.118731

62. Chobot, V., Hadacek, F. (2011). Exploration of pro-oxidant and antioxidant activities of the flavonoid myricetin. Redox Report, 16(6), 242–247. https://doi.org/10.1179/1351000211Y.0000000015

63. Sadžak, A., Vlašić, I., Kiralj, Z., Batarelo, M., Oršolić, N., Jembrek, M. J. et al. (2021). Neurotoxic effect of flavonol myricetin in the presence of excess copper. Molecules, 26(4), Article 845. https://doi.org/10.3390/molecules26040845

64. Kotik, M., Kulik, N., Valentová, K. (2023). Flavonoids as aglycones in retaining glycosidase-catalyzed reactions: Prospects for green chemistry. Journal of Agricultural and Food Chemistry, 71(41), 14890–14910. https://doi.org/10.1021/acs.jafc.3c04389

65. Crespy, V., Morand, C., Besson, C., Manach, C., Demigne, C., Remesy, C. (2002). Quercetin, but not its glycosides, is absorbed from the rat stomach. Journal of Agricultural and Food Chemistry, 50(3), 618–621. https://doi.org/10.1021/jf010919h

66. Xiang, D., Wang, C. -g., Wang, W. -q., Shi, C. -y., Xiong, W., Wang, M. -d. et al. (2017). Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: An in vitro investigation. International Journal of Food Sciences and Nutrition, 68(6), 704–711. https://doi.org/10.1080/09637486.2016.1276518

67. Boronat, A., Rodriguez-Morató, J., Serreli, G., Fitó, M., Tyndale, R. F., Deiana, M. et al. (2021). Contribution of biotransformations carried out by the microbiota, drug-metabolizing enzymes, and transport proteins to the biological activities of phytochemicals found in the diet. Advances in Nutrition, 12(6), 2172–2189. https://doi.org/10.1093/advances/nmab085

68. Dombi, A., Kaci, H., Valentová, K., Bakos, E., Özvegy-Laczka, C., Poór, M. (2024). Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). Pharmacology Research and Perspectives, 12(5), Article e70021. https://doi.org/10.1002/prp2.70021

69. Pluta, R., Januszewski, S., Czuczwar, S. J. (2021). Myricetin as a promising molecule for the treatment of post-ischemic brain neurodegeneration. Nutrients, 13(2), Article 342. https://doi.org/10.3390/nu13020342

70. Wang, X., Sun, Y., Li, P., Wu, Z., Chen, Y., Fu, Y. et al. (2023). The protective effects of myricetin against acute liver failure via inhibiting inflammation and regulating oxidative stress via Nrf2 signaling. Natural Product Research, 37(5), 798–802. https://doi.org/10.1080/14786419.2022.2089138

71. Chomphen, L., Yamanont, P., Morales, N. P. (2024). Flavonoid metabolites in serum and urine after the ingestion of selected tropical fruits. Nutrients, 16(1), Article 161. https://doi.org/10.3390/nu16010161

72. Li, H., Li, H., Jiang, S., Xu, J., Cui, Y., Wang, H. et al. (2022). Study of the metabolism of myricetin in rat urine, plasma and feces by ultra-high-performance liquid chromatography. Biomedical Chromatography, 36(3), Article e5281. https://doi.org/10.1002/bmc.5281

73. Babotă, M., Frumuzachi, O., Tanase, C., Mocan, A. (2024). Efficacy of myricetin supplementation on glucose and lipid metabolism: A systematic review and meta-analysis of in vivo mice studies. Nutrients, 16(21), Article 3730. https://doi.org/10.3390/nu16213730

74. Narkhede, M., Adhao, V. S., Chinchole, P. P., Shejol, V. M., Titare, A. G. (2025). A review on myricetin and its pharmacological activities. International Journal of Biology Pharmacy and Allied Sciences, 14(3), 1489–1513. https://doi.org/10.31032/IJBPAS/2025/14.3.8788

75. Mierziak, J., Kostyn, K., Kulma, A. (2014). Flavonoids as important molecules of plant interactions with the environment. Molecules, 19(10), 16240–16265. https://doi.org/10.3390/molecules191016240

76. Chen, S., Zhang, F., da Silva, A. P. G., Simal-Gandara, J., Cao, H. (2025). Vitamin C prevents myricetin degradation in boiling water by reducing ortho-quinone intermediates. Food Chemistry, 481, Article 143926. https://doi.org/10.1016/j.foodchem.2025.143926

77. Hasnat, H., Shompa, S. A., Islam, M. M., Alam, S., Richi, F. T., Emon, N. U. et al. (2024). Flavonoids: A treasure house of prospective pharmacological potentials. Heliyon, 10(6), Article e27533. https://doi.org/10.1016/j.heliyon.2024.e27533

78. Xiong, H. -H., Lin, S. -Y., Chen, L. -L., Ouyang, K. -H., Wang, W.- J. (2023). The interaction between flavonoids and intestinal microbes: A review. Foods, 12(2), Article 320. https://doi.org/10.3390/foods12020320

79. Xia, S. -F., Le, G. -W., Wang, P., Qiu, Y. -Y., Tang, X. (2016). Regressive effect of myricetin on hepatic steatosis in mice fed a high-fat diet. Nutrients, 8(12), Article 799. https://doi.org/10.3390/nu8120799

80. Przybylski, T., Czerniel, J., Dobrosielski, J., Stawny, M. (2025). Flavonol technology: From the compounds’ chemistry to clinical research. Molecules, 30(15), Article 3113. https://doi.org/10.3390/molecules30153113

81. Guo, H., Chen, Y. F., Tang, Y., Qian, J. Q. (2020). Method for enhancing bioavailability of myricetin based on self-assembly of casein-myricetin nanomicelles. IET Nanobiotechnology, 14(3), 239–244. https://doi.org/10.1049/iet-nbt.2018.5431

82. Park, H. -s., Seo, C. -S., Baek, E. B., Rho, J. -h., Won, Y. -s., Kwun, H.-j. (2021). Gastroprotective effect of myricetin on ethanol-induced acute gastric injury in rats. Evidence-­Based Complementary and Alternative Medicine, 2021(1), Article 9968112. https://doi.org/10.1155/2021/9968112

83. Lin, T.-C., Yang, C.-Y., Wu, T.-H., Tseng, C.-H., Yen, F.-L. (2023). Myricetin nanofibers enhanced water solubility and skin penetration for increasing antioxidant and photoprotective activities. Pharmaceutics, 15(3), Article 906. https://doi.org/10.3390/pharmaceutics15030906

84. Syahputra, R. A., Dalimunthe, A., Utari, Z. D., Halim, P., Sukarno, M. A., Zainalabidin, S. et al. (2024). Nanotechnology and flavonoids: Current research and future perspectives on cardiovascular health. Journal of Functional Foods, 120, Article 106355. https://doi.org/10.1016/j.jff.2024.106355

85. Wu, L., Ran, L., Lang, H., Zhou, M., Yu, L., Yi, L. et al. (2019). Myricetin improves endurance capacity by inducing muscle fiber type conversion via miR‑499. Nutrition and Metabolism, 16(1), Article 27. https://doi.org/10.1186/s12986-019-0353-8

86. Chen, H., Lin, H., Xie, S., Huang, B., Qian, Y., Chen, K. et al. (2019). Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination. Toxicology and Applied Pharmacology, 365(1), 19–29. https://doi.org/10.1016/j.taap.2018.12.019

87. Yang, W., Su, J., Li, M., Li, T., Wang, X., Zhao, M. et al. (2021). Myricetin induces autophagy and cell cycle arrest of HCC by inhibiting MARCH1‑regulated Stat3 and p38 MAPK signaling pathways. Frontiers in Pharmacology, 12(1), Article 709526. https://doi.org/10.3389/fphar.2021.709526

88. Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V. et al. (2017). Oxidative stress: Harms and benefits for human health. Oxidative Medicine and Cellular Longevity, 2017(1), Article 8416763. https://doi.org/10.1155/2017/8416763

89. Chong, Z. Z., Souayah, N. (2025). Oxidative stress: Pathological driver in chronic neurodegenerative diseases. Antioxidants, 14(6), Article 696. https://doi.org/10.3390/antiox14060696

90. Minocha, T., Birla, H., Obaid, A. A., Rai, V., Sushma, P., Shivamallu, C. et al. (2022). Flavonoids as promising neuroprotectants and their therapeutic potential against Alzheimer’s disease. Oxidative Medicine and Cellular Longevity, 2022(1), Article 6038996. https://doi.org/10.1155/2022/6038996

91. Tada, Y., Suzuki, J.-I. (2016). Oxidative stress and myocarditis. Current Pharmaceutical Design, 22(4), 450–471. https://doi.org/10.2174/1381612822666151222160559

92. Hirao, Y., Kobayashi, H., Mori, Y., Kato, S., Kawanishi, S., Murata, M. et al. (2023). Myricetin causes site-specific DNA damage via reactive oxygen species generation by redox interactions with copper ions. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 891, Article 503694. https://doi.org/10.1016/j.mrgentox.2023.503694

93. Chaudhary, P., Janmeda, P., Docea, A. O., Yeskaliyeva, B., Razis, A. F. A., Modu, B. et al. (2023). Oxidative stress, free radicals and antioxidants: Potential crosstalk in the pathophysiology of human diseases. Frontiers in Chemistry, 11(1), Article 1158198. https://doi.org/10.3389/fchem.2023.1158198

94. Yang, Z.-J., Wang, H.-R., Wang, Y.-I., Zhai, Z.-H., Wang, L.-W., Li, L. et al. (2019). Myricetin attenuated diabetes-associated kidney injuries and dysfunction via regulating nuclear factor (erythroid derived 2)-like 2 and nuclear factor-κB signaling. Frontiers in Pharmacology, 10, Article 647. https://doi.org/10.3389/fphar.2019.00647

95. Li, W., Kong, A. -N. (2009). Molecular mechanisms of Nrf2‑mediated antioxidant response. Molecular Carcinogenesis, 48(2), 91–104. https://doi.org/10.1002/mc.20465

96. Jomová, K., Raptová, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., Vaľko, M. (2023). Reactive oxygen species, toxicity, oxidative stress, and antioxidants: Chronic diseases and aging. Archives of Toxicology, 97(10), 2499–2574. https://doi.org/10.1007/s00204-023-03562-9

97. Suraweera, T. L., Rupasinghe, H. P. V., Dellaire, G., Xu, Z. (2020). Regulation of Nrf2/ARE pathway by dietary flavonoids: A friend or foe for cancer management? Antioxidants, 9(10), Article 973. https://doi.org/10.3390/antiox9100973

98. Rosa, A. C., Corsi, D., Cavi, N., Bruni, N., Dosio, F. (2021). Superoxide dismutase administration: A review of proposed human uses. Molecules, 26(7), Article 1844. https://doi.org/10.3390/molecules26071844

99. Chobot, V., Hadacek, F., Bachmann, G., Weckwerth, W., Kubicova, L. (2020). In vitro evaluation of pro- and antioxidant effects of flavonoid tricetin in comparison to myricetin. Molecules, 25(24), Article 5850. https://doi.org/10.3390/molecules25245850

100. Silva-Pinto, P. A., de Pontes, J. T. C., Aguilar-Morón, B., Canales, C. S. C., Pavan, F. R., Roque-Borda, C. A. (2025). Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin. Heliyon, 11(4), Article e42682. https://doi.org/10.1016/j.heliyon.2025.e42682

101. Yang, L., Li, X., Ni, L., Lin, Y. (2025). Treatment of endothelial cell dysfunction in atherosclerosis: A new perspective integrating traditional and modern approaches. Frontiers in Physiology, 16(1), Article 1555118. https://doi.org/10.3389/fphys.2025.1555118

102. Gu, S.-C., Xie, Z.-G., Gu, M.-J., Wang, C.-D., Xu, L.-M., Gao, C. et al. (2024). Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson’s disease. Scientific Reports, 14(1), Article 15107. https://doi.org/10.1038/s41598-024-62910-6

103. Chen, L., Fan, T., Wang, M., Zhu, C.-Y., Feng, W.-Y., Li, Y. et al. (2024). Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer. Expert Opinion on Therapeutic Targets, 28(1–2), 83–95. https://doi.org/10.1080/14728222.2024.2306345

104. Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., Ross, O. A. (2018). Age and age-related diseases: Role of inflammation triggers and cytokines. Frontiers in Immunology, 9(1), Article 586. https://doi.org/10.3389/fimmu.2018.00586

105. Liu, T., Zhang, L., Joo, D., Sun, S.-C. (2017). NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy, 2(1), Article e17023. https://doi.org/10.1038/sigtrans.2017.23

106. Wang, S.-J., Tong, Y., Lu, S., Yang, R., Liao, X., Xu, Y.-F. et al. (2010). Anti-inflammatory activity of myricetin isolated from Myrica rubra Sieb. et Zucc. leaves. Planta Medica, 76(14), 1492–1496. https://doi.org/10.1055/s‑0030-1249780

107. de Oliveira Azevedo, A., Campos, J. J., de Souza, G. G., de Carvalho Veloso, C., Duarte, I. D. G., Braga, F. C. et al. (2015). Antinociceptive and anti-inflammatory effects of myricetin 3-O-β-galactoside isolated from Davilla elliptica: Involvement of the nitrergic system. Journal of Natural Medicines, 69(4), 487–493. https://doi.org/10.1007/s11418-015-0913-9

108. Oh, J.-H., Karadeniz, F., Lee, J. I., Park, S. Y., Seo, Y., Kong, C.-S. (2020). Anticatabolic and anti-inflammatory effects of myricetin 3-O-β-d-galactopyranoside in UVA-irradiated dermal cells via repression of MAPK/AP‑1 and activation of TGFβ/ Smad. Molecules, 25(6), Article 1331. https://doi.org/10.3390/molecules25061331

109. Mao, H., Zhao, X., Sun, S.-c. (2025). NF-κB in inflammation and cancer. Cellular and Molecular Immunology, 22(8), 811–839. https://doi.org/10.1038/s41423-025-01310‑w

110. Hunter, C. J., De Plaen, I. G. (2014). Inflammatory signaling in NEC: Role of NF-κB, cytokines and other inflammatory mediators. Pathophysiology, 21(1), 55–65. https://doi.org/10.1016/j.pathophys.2013.11.010

111. Hinz, M., Scheidereit, C. (2014). The IκB kinase complex in NF-κB regulation and beyond. EMBO Reports, 15(1), 46–61. https://doi.org/10.1002/embr.201337983

112. Yu, C., Wang, D., Yang, Z., Wang, T. (2022). Pharmacological effects of polyphenol phytochemicals on the intestinal inflammation via targeting TLR4/NF-κB signaling pathway. International Journal of Molecular Sciences, 23(13), Article 6939. https://doi.org/10.3390/ijms23136939

113. Hu, H., Hu, Z., Zhang, Y., Wan, H., Yin, Z., Li, L. et al. (2022). Myricetin inhibits pseudorabies virus infection through direct inactivation and activating host antiviral defense. Frontiers in Microbiology, 13(1), Article 985108. https://doi.org/10.3389/fmicb.2022.985108

114. Ju, Z., Li, M., Xu, J., Howell, D. C., Li, Z., Chen, F.-E. (2022). Recent development on COX‑2 inhibitors as promising anti-inflammatory agents: The past 10 years. Acta Pharmaceutica Sinica B, 12(6), 2790–2807. https://doi.org/10.1016/j.apsb.2022.01.002

115. Zarghi, A., Arfaei, S. (2011). Selective COX‑2 inhibitors: A review of their structure-activity relationships. Iranian Journal of Pharmaceutical Sciences, 10(4), 655–683.

116. Rosas-Martínez, M., Gutiérrez-Venegas, G. (2019). Myricetin inhibition of peptidoglycan-induced COX‑2 expression in H9c2 cardiomyocytes. Preventive Nutrition and Food Science, 24(2), 202–209. https://doi.org/10.3746/pnf.2019.24.2.202

117. Kumar, H. P. P., Panda, P., Karunakar, P., Shiksha, K., Singh, L., Ramesh, N. et al. (2019). Potential cyclooxygenase (COX‑2) enzyme inhibitors from Myrica nagi — from in-silico to in-vitro investigation. Pharmacognosy Magazine, 15(64), 280–287. https://doi.org/10.4103/pm.pm_56_19

118. Ysrafil, Y., Sapiun, Z., Slamet, N. S., Mohamad, F., Hartati, H., Damiti, S. A. et al. (2023). Anti-inflammatory activities of flavonoid derivates. ADMET and DMPK, 11(3), 331–359. https://doi.org/10.5599/admet.1918

119. Cinelli, M. A., Do, H. T., Miley, G. P., Silverman, R. B. (2020). Inducible nitric oxide synthase: Regulation, structure, and inhibition. Medicinal Research Reviews, 40(1), 158–189. https://doi.org/10.1002/med.21599

120. Knott, A. B., Bossy-Wetzel, E. (2010). Impact of nitric oxide on metabolism in health and age-related disease. Diabetes, Obesity and Metabolism, 12 (Suppl. 2), 126–133. https://doi.org/10.1111/j.1463-1326.2010.01267.x

121. Cho, B. O., Yin, H. H., Park, S. H., Byun, E. B., Ha, H. Y., Jang, S. I. (2016). Anti-inflammatory activity of myricetin from Diospyros lotus through suppression of NF-κB and STAT1 activation and Nrf2‑mediated HO‑1 induction in lipopolysaccharidestimulated RAW264.7 macrophages. Bioscience, Biotechnology, and Biochemistry, 80(8), 1520–1530. https://doi.org/10.1080/09168451.2016.1171697

122. Jang, J. -H., Lee, S. H., Jung, K., Yoo, H., Park, G. (2020). Inhibitory effects of myricetin on lipopolysaccharide-induced neuroinflammation. Brain Sciences, 10(1), Article 32. https://doi.org/10.3390/brainsci10010032

123. Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J. et al. (2020). Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 4(1), Article 100130. https://doi.org/10.1016/j.ajpc.2020.100130

124. Gao, C., Jiang, J., Tan, Y., Chen, S. (2023). Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 8(1), Article 359. https://doi.org/10.1038/s41392-023-01588-0

125. Ginwala, R., Bhavsar, R., Chigbu, D. I., Jain, P., Khan, Z. K. (2019). Potential role of flavonoids in treating chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. Antioxidants, 8(2), Article 35. https://doi.org/10.3390/antiox8020035

126. Ghilardi, S. J., O’Reilly, B. M., Sgro, A. E. (2020). Intracellular signaling dynamics and their role in coordinating tissue repair. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 12(3), Article e1479. https://doi.org/10.1002/wsbm.1479

127. He, W. -J., Lv, C. -H., Chen, Z., Shi, M., Zeng, C. -X., Hou, D. -X. et al. (2023). The regulatory effect of phytochemicals on chronic diseases by targeting Nrf2-ARE signaling pathway. Antioxidants, 12(2), Article 236. https://doi.org/10.3390/antiox12020236

128. Han, S. -H., Lee, J. -H., Woo, J. -S., Jung, G. H., Jung, S. -H., Han, E. -J. et al. (2022). Myricetin induces apoptosis through the MAPK pathway and regulates JNK-mediated autophagy in SK-BR‑3 cells. International Journal of Molecular Medicine, 49(4), Article 54. https://doi.org/10.3892/ijmm.2022.5110

129. Ma, Y. -T., Li, C., Shen, Y., You, W. -H., Han, M. -X., Mu, Y. -F. et al. (2025). Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer. Frontiers in Oncology, 15(1), Article 1533352. https://doi.org/10.3389/fonc.2025.1533352

130. Papaconstantinou, J. (2019). The role of signaling pathways of inflammation and oxidative stress in development of senescence and aging phenotypes in cardiovascular disease. Cells, 8(11), Article 1383. https://doi.org/10.3390/cells8111383

131. Ponte, L. G. S., Pavan, I. C. B., Mancini, M. C. S., da Silva, L. G. S., Morelli, A. P., Severino, M. B. et al. (2021). The hallmarks of flavonoids in cancer. Molecules, 26(7), Article 2029. https://doi.org/10.3390/molecules26072029

132. Lee, Y. S., Choi, E. M. (2010). Myricetin inhibits IL‑1β-induced inflammatory mediators in SW982 human synovial sarcoma cells. International Immunopharmacology, 10(7), 812–814. https://doi.org/10.1016/j.intimp.2010.04.010

133. Moghadam, S. E., Ebrahimi, S. N., Salehi, P., Farimani, M. M., Hamburger, M., Jabbarzadeh, E. (2017). Wound healing potential of chlorogenic acid and myricetin‑3-O-β-rhamnoside isolated from Parrotia persica. Molecules, 22(9), Article 1501. https://doi.org/10.3390/molecules22091501

134. Karar, J., Maity, A. (2011). PI3K/AKT/mTOR pathway in angiogenesis. Frontiers in Molecular Neuroscience, 4(1), Article 51. https://doi.org/10.3389/fnmol.2011.00051

135. Hashemi, M., Khosroshahi, E. M., Asadi, S., Tanha, M., Mohseni, F. G., Sagha, R. A. M. et al. (2025). Emerging roles of non-coding RNAs in modulating the PI3K/ Akt pathway in cancer. Non-coding RNA Research, 10(1), 1–15. https://doi.org/10.1016/j.ncrna.2024.08.002

136. Kwon, M., Jung, H. J. (2025). Anticancer potential of myricetin against Huh7-and Hep3B-derived liver cancer stem cells through the regulation of apoptosis, autophagy, and stemness. Biomolecules and Therapeutics, 33(4), 636–651. https://doi.org/10.4062/biomolther.2025.044

137. Zhou, M., Konigsberg, W. H., Hao, C., Pan, Y., Sun, J., Wang, X. (2023). Bioactivity and mechanisms of flavonoids in decreasing insulin resistance. Journal of Enzyme Inhibition and Medicin

138. Hardie, D. G., Ross, F. A., Hawley, S. A. (2012). AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 13(4), 251–262. https://doi.org/10.1038/nrm3311

139. Kjøbsted, R., Hingst, J. R., Fentz, J., Foretz, M., Sanz, M. N., Pehmøller, C. et al. (2018). AMPK in skeletal muscle function and metabolism. The FASEB Journal, 32(4), 1741–1777. https://doi.org/10.1096/fj.201700442R

140. Moon, D. O. (2024). Plant-derived flavonoids as AMPK activators: Unveiling their potential in type 2 diabetes management through mechanistic insights, docking studies, and pharmacokinetics. Applied Sciences, 14(19), Article 8607. https://doi.org/10.3390/app14198607

141. Fang, C., Pan, J., Qu, N., Lei, Y., Han, J., Zhang, J. et al. (2022). The AMPK pathway in fatty liver disease. Frontiers in Physiology, 13(1), Article 970292. https://doi.org/10.3389/fphys.2022.970292

142. Xie, Y., Wang, Y., Xiang, W., Wang, Q., Cao, Y. (2020). Molecular mechanisms of the action of myricetin in cancer. Mini Reviews in Medicinal Chemistry, 20(2), 123–133. https://doi.org/10.2174/1389557519666191018112756

143. Kim, M., Tian, R. (2011). Targeting AMPK for cardiac protection: Opportunities and challenges. Journal of Molecular and Cellular Cardiology, 51(4), 548–553. https://doi.org/10.1016/j.yjmcc.2010.12.004

144. Long, Y. C., Zierath, J. R. (2006). AMP-activated protein kinase signaling in metabolic regulation. Journal of Clinical Investigation, 116(7), 1776–1783. https://doi.org/10.1172/jci29044

145. Handy, D. E., Castro, R., Loscalzo, J. (2011). Epigenetic modifications: Basic mechanisms and role in cardiovascular disease. Circulation, 123(19), 2145–2156. https://doi.org/10.1161/CIRCULATIONAHA.110.956839

146. Kubatka, P., Mazurakova, A., Samec, M., Koklesova, L., Zhai, K., Al-Ishaq, R. K. et al. (2021). Flavonoids against non-physiologic inflammation attributed to cancer initiation, development, and progression — 3PM pathways. EPMA Journal, 12(4), 559–587. https://doi.org/10.1007/s13167-021-00257‑y

147. Su, L.-J., Mahabir, S., Ellison, G. L., McGuinn, L. A., Reid, B. C. (2012). Epigenetic contributions to the relationship between cancer and dietary intake of nutrients, bioactive food components, and environmental toxicants. Frontiers in Genetics, 2(1), Article 91. https://doi.org/10.3389/fgene.2011.00091

148. Meeran, S. M., Ahmed, A., Tollefsbol, T. O. (2010). Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clinical Epigenetics, 1, 101–116. https://doi.org/10.1007/s13148-010-0011-5

149. Takahashi, N., Yamaguchi, S., Ohtsuka, R., Takeda, M., Yoshida, T., Kosaka, T. et al. (2023). Gene expression analysis of antioxidant and DNA methylation on the rat liver after 4‑week wood preservative chromated copper arsenate exposure. Journal of Toxicologic Pathology, 36(1), 31–43. https://doi.org/10.1293/tox.2022-0093

150. Esmaeili, M., Blythe, S. A., Tobias, J. W., Zhang, K., Yang, J., Klein, P. S. (2020). Chromatin accessibility and histone acetylation in the regulation of competence in early development. Developmental Biology, 462(1), 20–35. https://doi.org/10.1016/j.ydbio.2020.02.013

151. Busch, C., Burkard, M., Leischner, C., Lauer, U. M., Frank, J., Venturelli, S. (2015). Epigenetic activities of flavonoids in the prevention and treatment of cancer. Clinical Epigenetics, 7(1), Article 64. https://doi.org/10.1186/s13148-015-0095‑z

152. Eckschlager, T., Plch, J., Stiborova, M., Hrabeta, J. (2017). Histone deacetylase inhibitors as anticancer drugs. International Journal of Molecular Sciences, 18(7), Article 1414. https://doi.org/10.3390/ijms18071414

153. Stachecka, J., Kolodziejski, P. A., Noak, M., Szczerbal, I. (2021). Alteration of active and repressive histone marks during adipogenic differentiation of porcine mesenchymal stem cells. Scientific Reports, 11(1), Article 1325. https://doi.org/10.1038/s41598-020-79384‑x

154. Prananda, A. T., Halim, P., Syahputra, R. A. (2025). Targeting miRNA with flavonoids: Unlocking novel pathways in cardiovascular disease management. Frontiers in Pharmacology, 16(1), Article 1532986. https://doi.org/10.3389/fphar.2025.1532986

155. Giuppi, M., La Salvia, A., Evangelista, J., Ghidini, M. (2021). The role and expression of angiogenesis-related miRNAs in gastric cancer. Biology, 10(2), Article 146. https://doi.org/10.3390/biology10020146

156. Mioc, M., Prodea, A., Racoviceanu, R., Mioc, A., Ghiulai, R., Milan, A. et al. (2022). Recent advances regarding the molecular mechanisms of triterpenic acids: A review (Part II). International Journal of Molecular Sciences, 23(16), Article 8896. https://doi.org/10.3390/ijms23147740

157. Statello, L., Guo, C.-J., Chen, L.-L., Huarte, M. (2021). Gene regulation by long non-coding RNAs and its biological functions. Nature Reviews Molecular Cell Biology, 22(2), 96–118. https://doi.org/10.1038/s41580-020-00315-9

158. Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., Dulak, J. (2016). Role of Nrf2/HO‑1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cellular and Molecular Life Sciences, 73(17), 3221–3247. https://doi.org/10.1007/s00018-016-2223-0

159. Masci, D., Puxeddu, M., Silvestri, R., La Regina, G. (2024). Targeting CBP and p300: Emerging anticancer agents. Molecules, 29(19), Article 4524. https://doi.org/10.3390/molecules29194524

160. Reed, S. M., Quelle, D. E. (2014). p53 acetylation: Regulation and consequences. Cancers, 7(1), 30–69. https://doi.org/10.3390/cancers7010030

161. Maissan, P., Mooij, E. J., Barberis, M. (2021). Sirtuins-mediated system-level regulation of mammalian tissues at the interface between metabolism and cell cycle: A systematic review. Biology, 10(3), Article 194. https://doi.org/10.3390/biology10030194

162. Aspriţoiu, V. M., Stoica, I., Bleotu, C., Diaconu, C. C. (2021). Epigenetic regulation of angiogenesis in development and tumors progression: Potential implications for cancer treatment. Frontiers in Cell and Developmental Biology, 9(1), Article 689962. https://doi.org/10.3389/fcell.2021.689962

163. Singh, S., Nagalakshmi, D., Sharma, K. K., Ravichandiran, V. (2021). Natural antioxidants for neuroinflammatory disorders and possible involvement of Nrf2 pathway: A review. Heliyon, 7(2), Article e06216. https://doi.org/10.1016/j.heliyon.2021.e06216

164. Li, J., Xiang, H., Huang, C., Lu, J. (2021). Pharmacological actions of myricetin in the nervous system: A comprehensive review of preclinical studies in animals and cell models. Frontiers in Pharmacology, 12(1), Article 797298. https://doi.org/10.3389/fphar.2021.797298

165. Berköz, M., Yıldırım, M., Yalın, S., İlhan, M., Yunusoğlu, O. (2020). Myricetin inhibits angiotensin converting enzyme and induces nitric oxide production in HUVEC cell line. General Physiology and Biophysics, 39(3), 249–258. https://doi.org/10.4149/gpb_2020007

166. Kim, G. D. (2017). Myricetin inhibits angiogenesis by inducing apoptosis and suppressing PI3K/Akt/mTOR signaling in endothelial cells. Journal of Cancer Prevention, 22(4), 219–227. https://doi.org/10.15430/jcp.2017.22.4.219

167. Niisato, N., Marunaka, Y. (2023). Therapeutic potential of multifunctional myricetin for treatment of type 2 diabetes mellitus. Frontiers in Nutrition, 10(1), Article 1175660. https://doi.org/10.3389/fnut.2023.1175660

168. Al-Ishaq, R. K., Abotaleb, M., Kubatka, P., Kajo, K., Büsselberg, D. (2019). Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels. Biomolecules, 9(9), Article 430. https://doi.org/10.3390/biom9090430

169. Kashtoh, H., Baek, K. -H. (2022). Recent updates on phytoconstituent alphaglucosidase inhibitors: An approach towards the treatment of type two diabetes. Plants, 11(20), Article 2722. https://doi.org/10.3390/plants11202722

170. Yang, W., Yang, M., Tian, Y., Jiang, Q., Loor, J. J., Cao, J. et al. (2022). Effect of myricetin on lipid metabolism in primary calf hepatocytes challenged with long-chain fatty acids. Metabolites, 12(11), Article 1071. https://doi.org/10.3390/metabo12111071

171. Kang, K. A., Wang, Z. H., Zhang, R., Piao, M. J., Kim, K. C., Kang, S. S. et al. (2010). Myricetin protects cells against oxidative stress-induced apoptosis via regulation of PI3K/Akt and MAPK signaling pathways. International Journal of Molecular Sciences, 11(11), 4348–4360. https://doi.org/10.3390/ijms11114348

172. Kimura, A. M., Tsuji, M., Yasumoto, T., Mori, Y., Oguchi, T., Tsuji, Y. et al. (2021). Myricetin prevents high molecular weight Aβ1–42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. Free Radical Biology and Medicine, 171(1), 232–244. https://doi.org/10.1016/j.freeradbiomed.2021.05.019

173. Dhanraj, V., Karuppaiah, J., Balakrishnan, R., Elangovan, N. (2018). Myricetin attenuates neurodegeneration and cognitive impairment in Parkinsonism. Frontiers in Bioscience — Elite, 10(3), 481–494. https://doi.org/10.2741/e835

174. Feng, J., Chen, X., Wang, Y., Du, Y., Sun, Q., Zang, W. et al. (2015). Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells. Molecular and Cellular Biochemistry, 408, 163–170. https://doi.org/10.1007/s11010-015-2492-1

175. Zhou, Z., Mao, W., Li, Y., Qi, C., He, Y. (2019). Myricetin inhibits breast tumor growth and angiogenesis by regulating VEGF/VEGFR2 and p38MAPK signaling pathways. The Anatomical Record, 302(12), 2186–2192. https://doi.org/10.1002/ar.24222

176. Motlhatlego, K. E., Abdalla, M. A., Leonard, C. M., Eloff, J. N., McGaw, L. J. (2020). Inhibitory effect of Newtonia extracts and myricetin‑3-O-rhamnoside (myricitrin) on bacterial biofilm formation. BMC Complementary Medicine and Therapies, 20(1), Article 358. https://doi.org/10.1186/s12906-020-03139-4

177. Zhang, Z., Cao, M., Shang, Z., Xu, J., Chen, X., Zhu, Z. et al. (2025). Research progress on the antibacterial activity of natural flavonoids. Antibiotics, 14(4), Article 334. https://doi.org/10.3390/antibiotics14040334

178. Zeng, D., Jiao, F., Yang, Y., Dou, S., Yu, J., Yu, X. et al. (2025). Myricetin potentiates antibiotics against resistant Pseudomonas aeruginosa by disrupting biofilm formation and inhibiting motility through FimX-mediated c-di-GMP signaling interference. Biology, 14(7), Article 859. https://doi.org/10.3390/biology14070859

179. Krzyżek, P., Migdał, P., Paluch, E., Karwańska, M., Wieliczko, A., Gościniak, G. (2021). Myricetin as an antivirulence compound interfering with a morphological transformation into coccoid forms and potentiating activity of antibiotics against Helicobacter pylori. International Journal of Molecular Sciences, 22(5), Article 2695. https://doi.org/10.3390/ijms22052695

180. Carević, T., Kolarević, S., Kolarević, M. K., Nestorović, N., Novović, K., Nikolić, B. et al. (2024). Citrus flavonoids diosmin, myricetin and neohesperidin as inhibitors of Pseudomonas aeruginosa: Evidence from antibiofilm, gene expression and in vivo analysis. Biomedicine and Pharmacotherapy, 181(1), Article 117642. https://doi.org/10.1016/j.biopha.2024.117642

181. Šudomová, M., Hassan, S. T. S. (2023). Flavonoids with anti-herpes simplex virus properties: Deciphering their mechanisms in disrupting the viral life cycle. Viruses, 15(12), Article 2340. https://doi.org/10.3390/v15122340

182. Pan, H., He, J., Yang, Z., Yao, X., Zhang, H., Li, R. et al. (2023). Myricetin possesses the potency against SARS-CoV‑2 infection through blocking viralentry facilitators and suppressing inflammation in rats and mice. Phytomedicine, 116(1), Article 154858. https://doi.org/10.1016/j.phymed.2023.154858

183. Song, Y., Zhao, X., Chen, Y., Yu, X., Su, T., Wang, J. et al. (2024). The antiviral activity of myricetin against pseudorabies virus through regulation of the type I interferon signaling pathway. Journal of Virology, 99(1), Article e0156724. https://doi.org/10.1128/jvi.01567-24

184. Badshah, S. L., Faisal, S., Muhammad, A., Poulson, B. G., Emwas, A. H., Jaremko, M. (2021). Antiviral activities of flavonoids. Biomedicine and Pharmacotherapy, 140(1), Article 111596. https://doi.org/10.1016/j.biopha.2021.111596

185. Muñoz, A. L., Cuéllar, A. F., Arévalo, G., Santamaría, B. D., Rodríguez, A. K., Buendía-Atencio, C. et al. (2023). Antiviral activity of myricetin glycosylated compounds isolated from Marcetia taxifolia against chikungunya virus. EXCLI Journal, 22, 716–731. https://doi.org/10.17179/excli2023–6242

186. Kocić-Tanackov, S., Dimić, G., Tanackov, I., Pejin, D., Mojović, L., Pejin, J. (2012). The inhibitory effect of oregano extract on the growth of Aspergillus spp. and on sterigmatocystin biosynthesis. LWT, 49(1), 14–20. https://doi.org/10.1016/j.lwt.2012.04.013

187. Meral, O. M., Aydin, M., Sumlu, E., Korucu, E. N., Ozturk, A. (2025). Myricetin exerts antibiofilm effects on Candida albicans by targeting the RAS1/cAMP/EFG1 pathway and disruption of the hyphal network. Journal of Fungi, 11(5), Article 398. https://doi.org/10.3390/jof11050398

188. Lee, H. -S., Kim, Y. (2022). Myricetin disturbs the cell wall integrity and increases the membrane permeability of Candida albicans. Journal of Microbiology and Biotechnology, 32(1), 37–45. https://doi.org/10.4014/jmb.2110.10014

189. Hosee, Y. N., Farhan, M. S., Shaban, S. A. (2025). The potential of medicinal plants in antifungal drug development: Mechanisms, synergies, and future directions. Journal of Mycology and Infection, 30(1), 1–17. https://doi.org/10.17966/JMI.2025.30.1.1

190. Nowak-Perlak, M., Olszowy, M., Woźniak, M. (2025). The natural defense: Anti-aging potential of plant-derived substances and technological solutions against photoaging. International Journal of Molecular Sciences, 26(16), Article 8061. https://doi.org/10.3390/ijms26168061

191. Kyselova, Z. (2011). Toxicological aspects of the use of phenolic compounds in disease prevention. Interdisciplinary Toxicology, 4(4), 173–183. https://doi.org/10.2478/v10102-011-0027-5

192. Bello, I., Bakkouri, A. S., Tabana, Y. M., Al-Hindi, B., Al-Mansoub, M. A., Mahmud, R. et al. (2016). Acute and sub-acute toxicity evaluation of the methanolic extract of Alstonia scholaris stem bark. Medical Sciences, 4(1), Article 4. https://doi.org/10.3390/medsci4010004

193. Alaryani, F. S. (2024). Myricetin ameliorates arsenic-induced hematological changes, immune dysfunction, oxidative stress, hepatic and renal injuries and promotes inflammatory genes in rats. Open Veterinary Journal, 14(7), 1677–1688. https://doi.org/10.5455/OVJ.2024.v14.i7.17

194. Lai, Y., Xi, Y., Shao, M., Cui, X., Wei, X., Li, L. et al. (2020). Myricetin reduces the reproductive toxicity of cyclophosphamide in male mice. Wei Sheng Yan Jiu, 49(5), 790–794. https://doi.org/10.19813/j.cnki.weishengyanjiu.2020.05.017 (In Chinese)

195. Hobbs, C. A., Swartz, C., Maronpot, R., Davis, J., Recio, L., Koyanagi, M. et al. (2015). Genotoxicity evaluation of the flavonoid, myricitrin, and its aglycone, myricetin. Food and Chemical Toxicology, 83(1), 283–292. https://doi.org/10.1016/j.fct.2015.06.016

196. Nallappan, D., Ong, K. C., Palanisamy, U. D., Chua, K. H., Kuppusamy, U. R. (2021). Safety assessment and oxidative stress evaluation of myricetin derivative-rich fraction from Syzygium malaccense in C57BL/6J mice. International Food Research Journal, 28(4), 803–815. https://doi.org/10.47836/ifrj.28.4.17

197. Dorato, M. A., Engelhardt, J. A. (2005). The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s). Regulatory Toxicology and Pharmacology, 42(3), 265–274. https://doi.org/10.1016/j.yrtph.2005.05.004

198. Organisation for Economic Co-operation and Development (OECD). (2022). OECD Guidance Document No. 24: Acute Oral Toxicity — Up-and-Down Procedure (Test No. 425). OECD Publishing, 2022.

199. Aneeshkumar, A. L., Suja, S. N. R., Vilash, V., Nair, R. R., Siril, E. A., Rajasekharan, S. N. (2018). Sub-chronic oral toxicity assessment (90 days) of ethanolic fraction of leaves of Neurocalyx calycinus (R. Br. Ex Benn.) Rob. in rodents: A lesser known ethnomedicinal plant from the Cholanaickan tribal community, India. Interdisciplinary Toxicology, 11(3), 221–235. https://doi.org/10.2478/intox‑2018-0021

200. Setiani, L. A., Sari, B. L., Muntaza, W. (2023). Prediction of carcinogenic, mutagenic, hepatotoxic, and LD50 toxicity of herbs Euphorbia hirta and Camellia sinensis leaf compounds as in silico antihypertensive agents. Journal of Research in Science Education, 9(Special Issue), 103–112. https://doi.org/10.29303/jppipa.v9iSpecialIssue.5900

201. Nair, A. B., Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy, 7(2), 27–31. https://doi.org/10.4103/0976-0105.177703

202. Batra, P., Sharma, A. K. (2013). Anti-cancer potential of flavonoids: Recent trends and future perspectives. 3 Biotech, 3(6), 439–459. https://doi.org/10.1007/s13205-013-0117-5

203. Guo, Y. J., Zheng, S. L. (2014). Effect of myricetin on cytochrome P450 isoforms CYP1A2, CYP2C9 and CYP3A4 in rats. Pharmazie, 69(4), 306–310.

204. Lou, D., Bao, S. -s., Li, Y. -h., Lin, Q. -m., Yang, S. -f., He, J. -y. (2019). Inhibitory mechanisms of myricetin on human and rat liver cytochrome P450 enzymes. European Journal of Drug Metabolism and Pharmacokinetics, 44(5), 611–618. https://doi.org/10.1007/s13318-019-00546‑y

205. Liu, L., Sun, S., Rui, H., Li, X. (2017). In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharmaceutical Biology, 55(1), 1868–1874. https://doi.org/10.1080/13880209.2017.1339284

206. Bhatt, S., Manhas, D., Kumar, V., Gour, A., Sharma, K., Dogra, A. et al. (2022). Effect of myricetin on CYP2C8 inhibition to assess the likelihood of drug interaction using in silico, in vitro, and in vivo approaches. ACS Omega, 7(15), 13260–13269. https://doi.org/10.1021/acsomega.2c00726

207. Choi, S. -J., Shin, S. -C., Choi, J. -S. (2011). Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: Possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Archives of Pharmacal Research, 34(2), 309–315. https://doi.org/10.1007/s12272-011-0217‑x

208. Ali, A., Memon, Z., Hameed, A., Ul-Haq, Z., Ali, M., Hafizur, R. M. (2025). Myricetin amplifies glucose-stimulated insulin secretion via the cAMP-PKA-Epac‑2 signaling cascade. Biomedicines, 13(6), Article 1447. https://doi.org/10.3390/biomedicines13061447

209. Barnes, G. D. (2020). Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology — American Society of Hematology Education Program, 2020(1), 642–648. https://doi.org/10.1182/hematology.2020000151

210. Zhang, X. H., Ma, Z. G., Rowlands, D. K., Gou, Y. L., Fok, K. L., Wong, H. Y. et al. (2012). Flavonoid myricetin modulates GABA(A) receptor activity through activation of Ca2+ channels and CaMK-II pathway. Evidence-­Based Complementary and Alternative Medicine, 2012(1), Article 758097. https://doi.org/10.1155/2012/758097

211. Qian, J., Meng, H., Xin, L., Xia, M., Shen, H., Li, G. et al. (2017). Self-nanoemulsifying drug delivery systems of myricetin: Formulation development, characterization, and in vitro and in vivo evaluation. Colloids and Surfaces B: Biointerfaces, 160(1), 101–109. https://doi.org/10.1016/j.colsurfb.2017.09.020

212. Lu, H., Zhang, S., Wang, J., Chen, Q. (2021). A review on polymer and lipidbased nanocarriers and its application to nano-pharmaceutical and food-based systems. Frontiers in Nutrition, 8(1), Article 783831. https://doi.org/10.3389/fnut.2021.783831

213. Coşkun, N., Sarıtaş, S., Bechelany, M., Karav, S. (2025). Polyphenols in foods and their use in the food industry: Enhancing the quality and nutritional value of functional foods. International Journal of Molecular Sciences, 26(12), Article 5803. https://doi.org/10.3390/ijms26125803

214. Pluta, R., Januszewski, S., Czuczwar, S. J. (2021). Myricetin as a promising molecule for the treatment of post-ischemic brain neurodegeneration. Nutrients, 13(2), Article 342. https://doi.org/10.3390/nu13020342

215. Kurniawan, M. A., Suwanti, L. T., Mufasirin, M., Suprihati, E., Hastutiek, P., Kusnoto, K. et al. (2025). Morphometric and molecular identification of Eimeria bovis and Eimeria zuernii on beef cattle in Lamongan, East Java, Indonesia. Jurnal Medik Veteriner, 8(1), 153-166. https://doi.org/10.20473/jmv.vol8.iss1.2025.153-16